Update on the use of rituximab for intractable rheumatoid arthritis

R John LooneyUniversity of Rochester, Rochester, New York, USAAbstract: It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an ina...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: R John Looney
Format: article
Langue:EN
Publié: Dove Medical Press 2009
Sujets:
Accès en ligne:https://doaj.org/article/967a4a12fae44754a99f5bcadd572bbe
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!